BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)
Abstract
The Program BATTLE seeks to establish individualized targeted therapy by prospectively examining patients tumor biomarker profiles and assigning them to corresponding targeted therapies with the expectation to yield a better clinical outcome. Based on common altered signaling pathways in lung cancer, the BATTLE Program proposes to develop four phase II trials for chemorefractory, advanced NSCLC patients: erlotinib, ZD6474, bexarotene with erlotinib, and sorafenib which target, respectively, EGFR, VEGF / VEGFR, retinoid X receptor and cyclin D1, and Ras / Raf signaling pathways. A novel adaptive randomization statistical design will be applied to the clinical trials to accelerate the identification of best-fit treatment for patients. We propose also to study the molecular mechanisms of response or resistance to these targeted agents, identify novel molecular features in tumors and surrogate tissues to correlate with tumor response or resistance to the agents and, finally, explore other novel targeted agents (RAD001 and perifosine) in combination and their mechanisms of action by targeting mTOR and PI3K/Akt signaling, and develop phase I trials to test these combinations.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2012
- Accession Number
- ADA600971
Entities
People
- Edward Kim
- Waunki Hong
Organizations
- The University of Texas MD Anderson Cancer Center